

INGRASSIA FISHER & LORENZ, P.C.

7150 E. CAMELBACK, SUITE 325
SCOTTSDALE, ARIZONA 85251
Telephone: (480) 385-5060
Facsimile: (480) 385-5061

RECEIVED
CENTRAL FAX CENTER

JAN 04 2005

FACSIMILE TRANSMITTAL SHEET

TO:	FROM: DKB RK
David K. Benson, Reg. No. 42,314	
COMPANY: USPTO	DATE: TUESDAY, JANUARY 04, 2005
FAX NUMBER: 703.872.9306	TOTAL NO. OF PAGES INCLUDING COVER: 43
PHONE NUMBER: 703.308.4357	SENDER'S REFERENCE NUMBER: H0005036-3002
RE: Supplemental Information Disclosure Statement	RECIPIENTS REFERENCE NUMBER: 40/621,168 10/17/2008

URGENT FOR REVIEW PLEASE COMMENT PLEASE REPLY PLEASE RECYCLE

NOTES/COMMENTS:

**FORMAL COMMUNICATION
INTENDED FOR ENTRY**

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAWS. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OR

Incomplete pages 19-43 missing

LAW OFFICES
KILYK & BOWERSOX, P.L.L.C.

Intellectual Property Law

LUKE A. KILYK* (PA, DC)
 LEONARD D. BOWERSOX
 ARASH BEHRAVESH* (MA)
 JASBIR SINGH
 MATTHEW T. GILL
 RALPH T. WEBB* (DC, TX, LA)
 SUSANNE M. HOPKINS

53 A East Lee Street
 WARRENTON, VA 20186

FAIRFAX OFFICE
 3603-E Chain Bridge Road
 Fairfax, Virginia 22030

Of Counsel:
 WILLIAM CHARLES JAMISON
 WILLIAM O. TROUSDELL* (PA, DC)

TEL.: (540) 428-1701
 FAC.: (540) 428-1720
 (540) 428-1721

Email: lkilyk@kbpatentlaw.com
 Website: http://www.kbpatentlaw.com

*Admitted only in states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

RECEIVED
 CENTRAL FAX CENTER

JAN 04 2005

DATE: January 4, 2005

TO: Examiner Robin Regina Waller
 Group Art Unit 1626
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/723,208
 For: NOVEL ARYLAMINOPROPANE ANALOGUES AND
 THEIR USE FOR THE TREATMENT OF GLAUCOMA
Our Ref: 2162 (3010-009-01)

FROM: Luke A. Kilyk, Esq. 

FAC. TEL. NO.: 1-703-872-9306

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 18

Items Attached: Amendment - 12 pages
 Supplemental Information Disclosure Statement -- 2 pages
 Form PTO-1449 -- 1 page
 Document -- 2 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on January 4, 2005.


Donald S. Prater
 Name (Print)


 Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on January 4, 2005.

Donald S. Prater
Name (Print)



Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HELLBERG et al.) Examiner: WALLER, Robin Regina
Application No.: 10/723,208)
 Group Art Unit: 1626
Filed: November 26, 2003)
 Confirmation No.: 8524
Docket No.: 2162 (3010-009-01))
 Customer No.: 33432

For: NOVEL ARYLAMINOPROPANE ANALOGUES AND THEIR USE FOR THE TREATMENT OF
GLAUCOMA

RECEIVED
CENTRAL FAX CENTER

JAN 04 2005

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 4, 2005

Sir:

This Amendment is in response to the Office Action dated October 4, 2004, for which the Examiner has set a three-month period for response, thus making a response due on or before January 4, 2005.

Please amend the above-identified application as follows:

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.